Real-time individualized therapy evaluation
A method of individually optimizing drug therapy to a patient that includes the steps of administering a dose of a radiolabeled drug or fluorescent tags or drugs with inherent fluorescent properties to the patient in connection with chemotherapy, collecting a sample from the patient, analyzing the sample producing an analysis, and using the analysis for developing a model for the patient.
1 . A method of individually optimizing drug therapy to a patient, comprising the steps of:
administering a dose of a radiolabeled drug or fluorescent tags or drugs with inherent fluorescent properties to the patient in connection with chemotherapy,
collecting a sample from the patient,
analyzing said sample producing an analysis, and
using said analysis for developing a model for the patient.
2 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of analyzing said sample producing an analysis comprises analyzing said sample by accelerator mass spectrometry producing an accelerator mass spectrometry analysis.
3 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of analyzing said sample producing an analysis comprises analyzing said sample by analyzing said sample with sensitive fluorimeters producing a fluorimeters analysis.
4 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of analyzing said sample producing an analysis comprises analyzing said sample by accelerator mass spectrometry producing an accelerator mass spectrometry analysis, and wherein said step of using said analysis for developing a model for the patient comprises using said accelerator mass spectrometry analysis for developing a model for the patient.
5 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of developing a model for the patient comprises developing a pharmacokinetic model for the patient.
6 . The method of individually optimizing drug therapy to a patient of claim 5 including using said pharmacokinetic model to select an optimal drug dose, type and dosing interval for the patient.
7 . The method of individually optimizing drug therapy to a patient of claim 5 including collecting an additional sample from the patient to continuously monitor the status of the therapy and detect any changes in the metabolic and kinetic profile to signify development of resistance to the drug.
8 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of developing a model for the patient comprises developing a metabolites model for the patient.
9 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of developing a model for the patient comprises developing a DNA adducts model for the patient.
10 . The method of individually optimizing drug therapy to a patient of claim 9 wherein said step of developing a DNA adducts model for the patient provides information regarding DNA-drug adduct formed for drugs designed to bind to DNA.
11 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of collecting a sample from the patient comprises collecting a blood sample.
12 . The method of individually optimizing drug therapy to a patient of claim 1 wherein said step of collecting a sample from the patient comprises collecting a tissue sample.
13 . A method of individually optimizing drug therapy to a patient, comprising the steps of:
administering a dose of a radiolabeled drug to the patient in connection with chemotherapy,
collecting a sample from the patient,
analyzing said sample by accelerator mass spectrometry producing an analysis, and
using said analysis for developing a model for the patient.
14 . The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of developing a model for the patient comprises developing a pharmacokinetic model for the patient.
15 . The method of individually optimizing drug therapy to a patient of claim 4 including using said pharmacokinetic model to select an optimal drug dose, type and dosing interval for the patient.
16 . The method of individually optimizing drug therapy to a patient of claim 4 including collecting an additional sample from the patient to continuously monitor the status of the therapy and detect any changes in the metabolic and kinetic profile to signify development of resistance to the drug.
17 . The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of developing a model for the patient comprises developing a metabolites model for the patient.
18 . The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of developing a model for the patient comprises developing a DNA adducts model for the patient.
19 . The method of individually optimizing drug therapy to a patient of claim 8 wherein said step of developing a DNA adducts model for the patient provides information regarding DNA-drug adduct formed for drugs designed to bind to DNA.
20 . The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of collecting a sample from the patient comprises collecting a blood sample.
21 . The method of individually optimizing drug therapy to a patient of claim 13 wherein said step of collecting a sample from the patient comprises collecting a tissue sample.